Chromium triacetate

Endpoint summary

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion

Endpoint conclusion:

adverse effect observed (sensitising)

Additional information:

To investigate the skin sensitising properties of Acetic acid, chromium salt, basic, a Local Lymph Node Assay (LLNA) according to OECD 429 and GLP was performed (Meurer and Honarvar, 2008). In a preliminary range-finding test, the maximum technically applicable concentration of the test substance was found to be 50% in dimethylformamide. Therefore, test substance concentrations of 10, 25 and 50% were applied once daily to the dorsal surface of both ears of 4 mice per group for 3 consecutive days. On Day 5, all mice were dosed with ³H-Methylthymidine. Five hours thereafter, the mice were sacrificed and their draining auricular lymph nodes were excised, pooled per group and a single cell suspension was prepared. The ³H-Methylthymidine incorporation was determined in a β-counter.

All animals survived the study period and no signs of toxicity or local skin irritation were observed. Stimulation indices of 7.42, 7.25 and 13.60 were recorded for test substance concentrations of 10, 25 and 50%, respectively. The EC3 for the test substance is < 10%.

Under the conditions tested, the substance was considered to be a skin sensitiser.

Migrated from Short description of key information:

Skin sensitisation (OECD 429, LLNA): sensitising (EC3 < 10%)

Justification for selection of skin sensitisation endpoint:

There is only one study available.

Respiratory sensitisation

Endpoint conclusion

Endpoint conclusion:

no study available

Justification for classification or non-classification

The available data on skin sensitisation of the test substance are conclusive and meet the criteria for classification. The substance has to be classified as skin sensitiser Cat. 1B according to Regulation (EC) 1272/2008 and according to Directive 67/548/EEC as Xi, R43.